Company news
EMV Capital PLC news in 2022
EMV Capital PLC's news releases, calls and decks from 2022, newest first.
PDS Biotech: Median Overall Survival announcement
December 28, 2022
PDS: HPV16 Head and Neck Cancer announcement
December 16, 2022
Board Changes; Options; Co-Investment Agreement
December 12, 2022
EMV C leads £4.2m round in 5G and SATCOM leader
November 29, 2022
PDS Q3 Results and Business Update
November 14, 2022
PDS reports presentation of data at cancer society
November 7, 2022
EMV Capital secures investment in Ventive
October 20, 2022
PDS completes End-of-Phase 2 meeting with FDA
October 3, 2022
Half-year Report
September 30, 2022
PDS Completes $35 Million Financing Agreement
August 25, 2022
Acquisition of 30% Vortex stake & new Vortex CEO
August 16, 2022
PDS Reports Q2 2022 Results & Business Update
August 8, 2022
Holding(s) in Company
June 28, 2022
Result of Placing and Total Voting Rights
June 22, 2022
Proposed Placing to raise at least £1.5 million
June 21, 2022
NetScientific to increase Q-Bot stake to 23.7%
June 17, 2022
Q-Bot secures £1.6m of investment to fund growth
June 15, 2022
PDS Granted FDA Fast Track Designation for PDS0101
June 6, 2022
PDS Biotech - new data for ongoing clinical trials
May 27, 2022
General Counsel Strategic Hire & Grant of Options
May 19, 2022
ProAxsis Update
May 16, 2022
Final Results
May 12, 2022
PDS Reports Q1 2022 Results & Business Update
May 11, 2022
Notice of Results & Investor Presentation
May 9, 2022
Acquisition of 30% of Vortex Biotech Holdings
May 6, 2022
PDS Provides Business Update & Full-Year Results
March 31, 2022
Publication of Shareholder Newsletter
March 4, 2022
PDS Announces Preliminary Safety Data on PDS0101
February 24, 2022
PDS Clinical Trial with Mayo Clinic
February 15, 2022
PDS Phase 2 Trial Update
February 2, 2022
PDS Announces Preclinical Data for PDS0202 Vaccine
January 28, 2022
PDS Granted Novel HPV16 Immunotherapy Patent
January 10, 2022
ProAxsis CEO End of Year Update
January 10, 2022